No Data
Bohr Pharmaceutical (02142) has submitted a new drug clinical trial application for the treatment of chronic obstructive pulmonary disease to the National Medical Products Administration.
Jingu Financial News | Hapo Pharmaceutical (02142) announced that the group has submitted an Investigational New Drug (IND) application for HBM9378 (or SKB378, as described by Sichuan Kelun Pharmaceuticals Co., Ltd. (06990) and the company's partner in developing HBM9378) to the National Medical Products Administration. The drug is a fully human anti-thymic stromal lymphopoietin (TSLP) antibody for the treatment of chronic obstructive pulmonary disease (COPD).
Sinolink Securities: Medical industry sentiment in the third quarter hovers at the bottom, focusing on the improvement prospects for the next 25 years.
In the third quarter, due to internal adjustments in the medical sector, changes in the overall consumer environment, and some medical insurance cost control policies still being implemented, the Q3 financial report continues to explore the bottom line of the business climate, with a recovery slower than expected.
Hong Kong stocks unusual movement | Collbio Biotech-B (06990) surged more than 8% in the morning trading session. The application for Lencansatumab Monoclonal Antibody new drug has been accepted, and there may be multiple products launched in the near fut
Haitong Biology-B (06990) rose more than 8% in the morning session, as of the time of publication, it was up 5.65%, trading at 187 Hong Kong dollars, with a turnover of 35.4396 million Hong Kong dollars.
Hong Kong stocks announcement | Health World Technology-B: LuX-Valve Plus TRAVEL II one-year clinical follow-up results will be released at the 2024 Transcatheter Cardiovascular Technology Conference in Washington, USA.
Ch Energy Eng (03996) controlling shareholder received financial support for the shareholding of A shares; following Takeda FRUZAQLA (Fruquintinib) sales exceeding 0.2 billion US dollars, Hutchmed (China) (00013) will receive the first commercial milestone payment.
Sichuan Kelun-Biotech Biopharmaceutical's Cancer Drug Gets NMPA's NDA Nod
Chelonobio Life Sciences -B (06990.HK): The new drug application for the core product Lukan Shatuzumab Monoclonal Antibody (SAC-TMT) has been accepted by the National Medical Products Administration.
Grain Alliance October 31st | Kelunbotai Biology-B (06990.HK) announced that the new drug application (NDA) for sac-TMT based on the positive results of the OptiTROP-Lung04 pivotal Phase III study, formerly known as SKB264/MK-2870, has been accepted by the China National Medical Products Administration (NMPA) Drug Evaluation Center (CDE), for the treatment of locally advanced or metastatic non-small cell lung cancer with EGFR mutation after EGFR-tyrosine kinase inhibitor (TKI) treatment.
No Data
No Data